Congress shields generic drugmakers from patent suits over off-label sales

What it does

This bill creates a legal safe harbor allowing generic drug and biosimilar manufacturers to develop, seek approval for, and market drugs without infringing method-of-use patents—provided their labeling does not claim the patented use. In practice, it permits generic makers to sell drugs for off-label uses (uses not covered by the patent) while the original patent holder retains exclusive rights to the patented indication. Patients and insurers benefit from lower-cost generics; patent holders lose exclusivity over non-patented uses.

Why we flagged it

The bill's core function is to create a statutory exemption from patent infringement liability for generic and biosimilar manufacturers under specified conditions. This is a targeted patent-law amendment, not a broad deregulation or subsidy.

What the text implies

• The safe harbor applies retroactively to all pending litigation and conduct before enactment, potentially invalidating ongoing patent infringement cases and settlements involving method-of-use claims.
• Generic makers can market drugs for non-patented uses without patent-holder consent, but patent holders retain exclusive rights to labeled patented indications—creating a bifurcated market where the same drug molecule may be sold at different prices for different uses.
• The safe harbor hinges on labeling compliance; generic makers must carefully avoid any reference to patented conditions of use, creating a compliance burden and potential for disputes over what constitutes a prohibited reference.
• Biosimilar manufacturers gain equivalent protection, potentially accelerating entry of lower-cost biologics and reducing exclusivity periods for reference products on non-patented indications.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and patients gain access to lower-cost generic and biosimilar drugs sooner, as manufacturers face reduced legal barriers to market entry. The safe harbor does not eliminate patent protection—it only shields generic makers from infringement liability when they avoid claiming the patented use, preserving incentives for innovation while enabling price competition on non-patented indications.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• pharmacy benefit managers and insurers (via lower drug costs)
• patients and consumers (via lower out-of-pocket costs)

Named in the bill

FDA (Food and Drug Administration), Patent and Trademark Office, generic drug manufacturers, biosimilar manufacturers, pharmaceutical patent holders, 35 U.S.C. § 271, Federal Food, Drug, and Cosmetic Act, Public Health Service Act

Where it stands

6 cosponsors: 3 Democrats, 3 Republicans.

• Dec 5, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 5, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

15 lobbying clients named this bill on 16 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $24,469,577 in lobbying spend. A filing names 28 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Ben Cline, the sponsor, reported $640,776 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Association for Accessible Medicines — $870,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.